| Date Filed | Type | Description |
| 02/14/2022 |
SC 13G/A
| Ikarian Capital, LLC reports a 3.5% stake in Odonate Therapeutics, Inc. |
| 02/10/2022 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 0% stake in Odonate Therapeutics, Inc. |
| 02/07/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/31/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/28/2022 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.4% stake in Odonate Therapeutics Inc |
| 01/28/2022 |
SC 13G
| BML Investment Partners, L.P. reports a 7.4% stake in Odonate Therapeutics Inc |
| 01/26/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/26/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/25/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/07/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 12/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/26/2021 |
SC 13D/A
| Boxer Capital, LLC reports a 10.9% stake in Odonate Therapeutics, Inc. |
| 11/22/2021 |
SC 13D/A
| Boxer Capital, LLC reports a 12% stake in Odonate Therapeutics, Inc. |
| 11/19/2021 |
SC 13D/A
| TANG CAPITAL PARTNERS LP reports a 33.7% stake in Odonate Therapeutics, Inc. |
| 11/18/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 11/18/2021 |
SC 13G/A
| EcoR1 Capital, LLC reports a 14.8% stake in Odonate Therapeutics, Inc. |
| 11/10/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/05/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/27/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/19/2021 |
SC 13G
| EcoR1 Capital, LLC reports a 8.7% stake in Odonate Therapeutics, Inc. |
| 07/02/2021 |
SC 13G
| Ikarian Capital, LLC reports a 5.2% stake in Odonate Therapeutics, Inc. |
| 06/25/2021 |
8-K
| Quarterly results |
| 06/01/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/14/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/25/2021 |
8-K
| Quarterly results |
| 02/23/2021 |
8-K
| Quarterly results |
| 02/23/2021 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/23/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
|